BR112022001690A2 - Tratamento de tumores imunes evasivos - Google Patents

Tratamento de tumores imunes evasivos

Info

Publication number
BR112022001690A2
BR112022001690A2 BR112022001690A BR112022001690A BR112022001690A2 BR 112022001690 A2 BR112022001690 A2 BR 112022001690A2 BR 112022001690 A BR112022001690 A BR 112022001690A BR 112022001690 A BR112022001690 A BR 112022001690A BR 112022001690 A2 BR112022001690 A2 BR 112022001690A2
Authority
BR
Brazil
Prior art keywords
evasive
treatment
immune
tumors
immune tumors
Prior art date
Application number
BR112022001690A
Other languages
English (en)
Inventor
Adam Elhofy
John Puisis
Joseph Podojil
Michael Boyne
Tushar Murthy
Original Assignee
Oncour Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncour Pharma Inc filed Critical Oncour Pharma Inc
Publication of BR112022001690A2 publication Critical patent/BR112022001690A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

tratamento de tumores imunes evasivos. a presente divulgação fornece métodos para tratar cânceres imunes evasivos usando partículas funcionalizadas em superfície sozinhas ou em combinação com produtos terapêuticos contra o câncer.
BR112022001690A 2019-07-31 2020-07-31 Tratamento de tumores imunes evasivos BR112022001690A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881326P 2019-07-31 2019-07-31
US202063018026P 2020-04-30 2020-04-30
PCT/US2020/044622 WO2021022218A1 (en) 2019-07-31 2020-07-31 Treatment of immune evasive tumors

Publications (1)

Publication Number Publication Date
BR112022001690A2 true BR112022001690A2 (pt) 2022-05-03

Family

ID=74230608

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001690A BR112022001690A2 (pt) 2019-07-31 2020-07-31 Tratamento de tumores imunes evasivos

Country Status (11)

Country Link
US (1) US20220257768A1 (pt)
EP (1) EP4003994A4 (pt)
JP (1) JP2022542461A (pt)
KR (1) KR20220054305A (pt)
CN (1) CN114502557A (pt)
AU (1) AU2020322046A1 (pt)
BR (1) BR112022001690A2 (pt)
CA (1) CA3149308A1 (pt)
IL (1) IL290130A (pt)
MX (1) MX2022001249A (pt)
WO (1) WO2021022218A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549555A (ja) 2020-11-18 2023-11-27 パイオニア イミュノセラピューティクス インコーポレイテッド 抗ｍａｒｃｏ抗体及びその使用
US20240336893A1 (en) * 2021-07-28 2024-10-10 H. Lee Moffitt Cancer Center And Research Institute Inc. Gene signature predicting tertiary lymphoid structures containing b cells
CN114480280B (zh) * 2022-03-02 2023-09-29 中国科学院理化技术研究所 烟草花叶病毒在刺激巨噬细胞极化为m1型巨噬细胞中应用
CN115944650B (zh) * 2023-01-03 2023-11-28 青岛大学 肿瘤浸润细胞在制备抗肿瘤药物中的应用及模型构建方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086639A2 (en) * 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
WO2009123735A1 (en) * 2008-04-04 2009-10-08 The Regents Of The University Of California Use of functionalized magnetic nanoparticles in cancer detection and treatment
CN114099461A (zh) * 2013-03-13 2022-03-01 onCOUR制药股份有限公司 用于治疗炎症的免疫修饰性颗粒
HUE047329T2 (hu) * 2013-08-13 2020-04-28 Univ Northwestern Peptiddel konjugált részecskék
US20200179528A9 (en) * 2015-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Immune cell-targeted particles
WO2018122249A1 (en) * 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2019149743A1 (en) * 2018-01-30 2019-08-08 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
JP2021532136A (ja) * 2018-07-31 2021-11-25 オンコア ファーマ，インコーポレイテッド がんの治療のための免疫調節粒子
US20210393620A1 (en) * 2018-09-24 2021-12-23 Sierra Oncology, Inc. Methods of Treatment of Cancer Comprising CDC7 Inhibitors

Also Published As

Publication number Publication date
KR20220054305A (ko) 2022-05-02
EP4003994A4 (en) 2023-09-13
WO2021022218A1 (en) 2021-02-04
US20220257768A1 (en) 2022-08-18
CN114502557A (zh) 2022-05-13
EP4003994A1 (en) 2022-06-01
MX2022001249A (es) 2022-05-03
IL290130A (en) 2022-03-01
AU2020322046A1 (en) 2022-03-10
CA3149308A1 (en) 2021-02-04
JP2022542461A (ja) 2022-10-03

Similar Documents

Publication Publication Date Title
BR112022001690A2 (pt) Tratamento de tumores imunes evasivos
BR112019010020A2 (pt) compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX2017013178A (es) Terapia de combinacion para cancer.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
PH12018500869A1 (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2022003571A (es) Uso de un anticuerpo anti-pd-1 en combinacion con un anticuerpo anti- cd30 para el tratamiento de linfoma.
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
MX2021005761A (es) Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
MX2020001727A (es) Terapia de combinacion.
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112018075660A2 (pt) métodos de tratamento de câncer de pâncreas
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
BR112018009753A2 (pt) bactérias de virulência atenuada para o tratamento de tumores sólidos malignos
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
PH12021550035A1 (en) Combination therapy
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 471/22

Ipc: C07D 471/22 (2006.01), A61K 31/765 (2006.01), A61K